“…The VFQ-25 has been used to measure VR-QoL in several chronic ocular diseases, such as glaucoma, keratoconus, adult macular degeneration, uveitis and DME (Aydin Kurna et al, 2014;Cahill, Banks, Stinnett, & Toth, 2005;Freedman et al, 2014;Jivraj, Jivraj, Tennant, & Rudnisky, 2013;Kaleemunnisha et al, 2014;Lightman et al, 2013;Miskala et al, 2004;Sakai et al, 2013). The RESTORE trial (Mitchell et al, 2013) is the first to assess the impact of ranibizumab treatment on health related quality of life (HR-QoL) using the VFQ-25.…”